Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | VNN1 | O95497 | 3/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664920 | 0.88 | CES2 (0.47) | CES2CES1CYP4F2CYP4A11SRD5A2 | |
| SCHEMBL1002846 | 0.80 | CES2 (0.53) | CES2CES1CYP4F2CYP4A11VNN1 | |
| SCHEMBL1426328 | 0.76 | CES2 (0.48) | CES2CES1CYP4F2CYP4A11VNN1 | |
| SCHEMBL13664925 | 0.75 | CES2 (0.47) | CES2CES1VNN1MAOAMAOB | |
| SCHEMBL2093205 | 0.74 | CYP4F2 (0.50) | CYP4F2CYP4A11PTGER4ACHEHDAC1 | |
| SCHEMBL1627397 | 0.73 | NR1H4 (0.51) | CYP4F2CYP4A11SRD5A2PTGER4 | |
| SCHEMBL13991056 | 0.73 | CES2 (0.57) | CES2CES1VNN1HSD17B1HSD17B2 | |
| SCHEMBL15238379 | 0.73 | CYP4F2 (0.46) | CYP4F2CYP4A11SRD5A2MAOAMAOB | |
| SCHEMBL1004288 | 0.72 | SRD5A2 (0.43) | CES2CES1CYP4F2CYP4A11SRD5A2 | |
| SCHEMBL7967901 | 0.72 | CES2 (0.73) | CES2CES1VNN1HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | CES2 1262/4885CES1 758/4885CYP4F2 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.